India’s Bharat Biotech says Covaxin booster shot neutralises Omicron

NEW DELHI, Jan 12 (Reuters) – India’s Bharat Biotech said on Wednesday a booster shot of its Covaxin COVID-19 vaccine administered six months after the last of two doses neutralises both the Omicron and Delta variants of the coronavirus.

The study was conducted at the Emory Vaccine Center in Atlanta based on blood serum collected from 13 individuals, 28 days after their booster shot. It was sponsored by Bharat Biotech’s partner Ocugen Inc (OCGN.O).

A woman receives a booster dose of Covaxin, a coronavirus disease (COVID-19) vaccine manufactured by Bharat Biotech, at a vaccination centre in New Delhi, India, January 10, 2022. REUTERS/Adnan Abidi

“The neutralisation activity of Covaxin-boosted sera was comparable to what has been observed in mRNA vaccine-boosted sera against the Omicron variant,” Bharat Biotech said in a statement. “More than 90% of all individuals boosted with Covaxin showed neutralising antibodies.”

Covaxin, India’s first domestically developed COVID-19 vaccine, received a WHO emergency-use listing late last year. More than 201 million doses of it have been administered in the country.

Reporting by Krishna N. Das, Editing by Louise Heavens and Alex Richardson

Our Standards: The Thomson Reuters Trust Principles.

Reuters source: